Literature DB >> 19515870

Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization.

Adriana Weinberg1, Lin-Ye Song, Cynthia Wilkening, Anne Sevin, Bruce Blais, Raul Louzao, Dana Stein, Patricia Defechereux, Deborah Durand, Eric Riedel, Nancy Raftery, Renee Jesser, Betty Brown, M Fran Keller, Ruth Dickover, Elizabeth McFarland, Terence Fenton.   

Abstract

The goals of this study were to optimize processing methods of cryopreserved peripheral blood mononuclear cells (PBMC) for immunological assays, identify acceptance parameters for the use of cryopreserved PBMC for functional and phenotypic assays, and to define limitations of the information obtainable with cryopreserved PBMC. Blood samples from 104 volunteers (49 human immunodeficiency virus-infected and 55 uninfected) were used to assess lymphocyte proliferation in response to tetanus, candida, and pokeweed-mitogen stimulation and to enumerate CD4(+) and CD8(+) T cells and T-cell subpopulations by flow cytometry. We determined that slowly diluting the thawed PBMC significantly improved viable cell recovery, whereas the use of benzonase improved cell recovery only sometimes. Cell storage in liquid nitrogen for up to 15 months did not affect cell viability, recovery, or the results of lymphocyte proliferation assays (LPA) and flow cytometry assays. Storage at -70 degrees C for < or =3 weeks versus storage in liquid nitrogen before shipment on dry ice did not affect cell viability, recovery, or flow cytometric results. Storage at -70 degrees C was associated with slightly higher LPA results with pokeweed-mitogen but not with microbial antigens. Cell viability of 75% was the acceptance parameter for LPA. No other acceptance parameters were found for LPA or flow cytometry assay results for cryopreserved PBMC. Under optimized conditions, LPA and flow cytometry assay results for cryopreserved and fresh PBMC were highly correlated, with the exception of phenotypic assays that used CD45RO or CD62L markers, which seemed labile to freezing and thawing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515870      PMCID: PMC2725535          DOI: 10.1128/CVI.00342-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  19 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

2.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Authors:  Olivier Lambotte; Faroudy Boufassa; Yoann Madec; Ahn Nguyen; Cécile Goujard; Laurence Meyer; Christine Rouzioux; Alain Venet; Jean-François Delfraissy
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

3.  Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.

Authors:  Wayne B Dyer; Sarah L Pett; John S Sullivan; Sean Emery; David A Cooper; Anthony D Kelleher; Andrew Lloyd; Sharon R Lewin
Journal:  Clin Vaccine Immunol       Date:  2006-10-18

4.  Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  Adriana Weinberg; Camlin Tierney; Michelle A Kendall; Ronald J Bosch; Julie Patterson-Bartlett; Alejo Erice; Martin S Hirsch; Bruce Polsky
Journal:  J Infect Dis       Date:  2006-01-03       Impact factor: 5.226

5.  Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.

Authors:  Valérie Martinez; Dominique Costagliola; Olivia Bonduelle; Nicole N'go; Aurélie Schnuriger; Ioannis Théodorou; Jean-Pierre Clauvel; Didier Sicard; Henri Agut; Patrice Debré; Christine Rouzioux; Brigitte Autran
Journal:  J Infect Dis       Date:  2005-05-10       Impact factor: 5.226

6.  Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients.

Authors:  A Weinberg; R A Betensky; L Zhang; G Ray
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

7.  Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study.

Authors:  C A Kleeberger; R H Lyles; J B Margolick; C R Rinaldo; J P Phair; J V Giorgi
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

8.  Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.

Authors:  William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector
Journal:  J Allergy Clin Immunol       Date:  2003-11       Impact factor: 10.793

9.  Effects of cryopreservation on lymphocyte immunophenotype and function.

Authors:  A Costantini; S Mancini; S Giuliodoro; L Butini; C M Regnery; G Silvestri; M Montroni
Journal:  J Immunol Methods       Date:  2003-07       Impact factor: 2.303

10.  Standardization of cytokine flow cytometry assays.

Authors:  Holden T Maecker; Aline Rinfret; Patricia D'Souza; Janice Darden; Eva Roig; Claire Landry; Peter Hayes; Josephine Birungi; Omu Anzala; Miguel Garcia; Alexandre Harari; Ian Frank; Ruth Baydo; Megan Baker; Jennifer Holbrook; Janet Ottinger; Laurie Lamoreaux; C Lorrie Epling; Elizabeth Sinclair; Maria A Suni; Kara Punt; Sandra Calarota; Sophia El-Bahi; Gailet Alter; Hazel Maila; Ellen Kuta; Josephine Cox; Clive Gray; Marcus Altfeld; Nolwenn Nougarede; Jean Boyer; Lynda Tussey; Timothy Tobery; Barry Bredt; Mario Roederer; Richard Koup; Vernon C Maino; Kent Weinhold; Giuseppe Pantaleo; Jill Gilmour; Helen Horton; Rafick P Sekaly
Journal:  BMC Immunol       Date:  2005-06-24       Impact factor: 3.615

View more
  72 in total

1.  Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot.

Authors:  Johannes Trück; Ruth Mitchell; Amber J Thompson; Begonia Morales-Aza; Elizabeth A Clutterbuck; Dominic F Kelly; Adam Finn; Andrew J Pollard
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies.

Authors:  Sabine Ivison; Mehrnoush Malek; Rosa V Garcia; Raewyn Broady; Anne Halpin; Manon Richaud; Rollin F Brant; Szu-I Wang; Mathieu Goupil; Qingdong Guan; Peter Ashton; Jason Warren; Amr Rajab; Simon Urschel; Deepali Kumar; Mathias Streitz; Birgit Sawitzki; Stephan Schlickeiser; Janetta J Bijl; Donna A Wall; Jean-Sebastien Delisle; Lori J West; Ryan R Brinkman; Megan K Levings
Journal:  JCI Insight       Date:  2018-12-06

3.  Viable mononuclear cell stability study for implementation in a proficiency testing program: impact of shipment conditions.

Authors:  Olga A Kofanova; Kristine Davis; Barbara Glazer; Yvonne De Souza; Joseph Kessler; Fotini Betsou
Journal:  Biopreserv Biobank       Date:  2014-06       Impact factor: 2.300

4.  Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Authors:  Mark H Kuniholm; Xianhong Xie; Kathryn Anastos; Robert C Kaplan; Xiaonan Xue; Andrea Kovacs; Marion G Peters; Eric C Seaberg; Audrey L French; Mary A Young; Michael Augenbraun; Jeffrey A Martinson; Kristin A Bush; Alan L Landay; Howard D Strickler
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

5.  Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73.

Authors:  Ross J Turner; Nicholas J Geraghty; Jonathan G Williams; Diane Ly; Daniel Brungs; Martin G Carolan; Thomas V Guy; Debbie Watson; Jeremiah F de Leon; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2020-08-05       Impact factor: 3.765

6.  Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

Authors:  Kent J Weinhold; Jack F Bukowski; Todd V Brennan; Robert J Noveck; Janet S Staats; Liwen Lin; Linda Stempora; Constance Hammond; Ann Wouters; Christopher F Mojcik; John Cheng; Mark Collinge; Michael I Jesson; Anasuya Hazra; Pinaki Biswas; Shuping Lan; James D Clark; Jennifer A Hodge
Journal:  Clin Immunol       Date:  2018-03-05       Impact factor: 3.969

Review 7.  Standardizing immunophenotyping for the Human Immunology Project.

Authors:  Holden T Maecker; J Philip McCoy; Robert Nussenblatt
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

8.  Isolation, Cryopreservation, and Immunophenotyping of Human Peripheral Blood Mononuclear Cells.

Authors:  Fredine T Lauer; Jesse L Denson; Scott W Burchiel
Journal:  Curr Protoc Toxicol       Date:  2017-11-08

9.  High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088).

Authors:  Adriana Weinberg; Petronella Muresan; Terence Fenton; Kelly Richardson; Teresa Dominguez; Anthony Bloom; Elizabeth Petzold; Patricia Anthony; Coleen K Cunningham; Stephen A Spector; Sharon Nachman; George K Siberry; Edward Handelsman; Patricia M Flynn
Journal:  Hum Vaccin Immunother       Date:  2013-01-31       Impact factor: 3.452

10.  Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Authors:  A Mander; C Gouttefangeas; C Ottensmeier; M J P Welters; L Low; S H van der Burg; C M Britten
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.